MannKind Corp’s Chief Financial Officer Christopher B. Prentiss received new equity awards. He was granted 221,000 performance-based restricted stock units, each representing a right to one share of common stock, and 217,000 employee stock options with a $2.44 exercise price, all held directly.
The performance units vest on January 15, 2029, with actual payout from 0% to 300% of the 221,000-share target based on MannKind’s total shareholder return from April 1, 2026 through December 31, 2028 versus the Russell 3000 Pharmaceutical & Biotechnology Index. The options vest 25% on March 23, 2027 and then 1/16 quarterly until fully vested, and expire on March 23, 2036.
MannKind Corp Chief Executive Officer Michael Castagna received new equity compensation awards. He was granted 796,000 performance-based restricted stock units, each representing the right to receive one share of common stock. The actual shares that vest on January 15, 2029 can range from 0% to 300% of this target, based on MannKind’s total shareholder return from April 1, 2026 to December 31, 2028 versus the Russell 3000 Pharmaceutical & Biotechnology Index.
He was also granted stock options for 782,000 shares of common stock at an exercise price of $2.4400 per share, expiring on March 23, 2036. These options vest 25% on March 23, 2027 and the remaining portion in equal quarterly installments over four years.
MannKind Corp reported new equity awards for EVP Technical Operations Sanjay R. Singh. He received 221,000 performance-based restricted stock units, each tied to one common share, that vest on January 15, 2029 with payout ranging from 0% to 300% of target based on relative total shareholder return versus the Russell 3000 Pharmaceutical & Biotechnology Index from April 1, 2026 through December 31, 2028. He was also granted options on 217,000 shares at an exercise price of $2.44 per share, vesting 25% on March 23, 2027 and the remainder in equal quarterly installments through 2031, expiring March 23, 2036. These are compensation-related grants, not open-market trades.
MannKind Corporation’s Chief Medical Officer, Ajay Ahuja, reported new equity awards. He received 221,000 performance-based restricted stock units, each representing a right to one share of common stock. These units vest on January 15, 2029, with the actual payout ranging from 0% to 300% of the target based on MannKind’s total shareholder return versus the Russell 3000 Pharmaceutical & Biotechnology Index from April 1, 2026 through December 31, 2028.
He was also granted options on 217,000 shares of common stock at an exercise price of $2.44 per share. These options vest 25% on March 23, 2027, with the remaining 75% vesting in 1/16th increments quarterly, and expire on March 23, 2036. All positions are held directly and reflect compensation awards rather than market purchases or sales.
MannKind Corp granted Chief People & Workplace Officer Stuart A. Tross new equity awards. He received 221,000 performance-based restricted stock units, each representing the right to one share of common stock. These units vest on January 15, 2029, with the payout from 0% to 300% of target based on MannKind’s total shareholder return versus the Russell 3000 Pharmaceutical & Biotechnology Index from April 1, 2026 through December 31, 2028.
He was also granted 217,000 stock options with a $2.44 exercise price, expiring on March 23, 2036. These options vest 25% on March 23, 2027, with the remaining 75% vesting in equal quarterly installments over four years.
MannKind Corp EVP and General Counsel David Thomson reported equity awards, not open-market trades. He received 221,000 performance-based restricted stock units, each representing a contingent right to one share of common stock.
The performance units vest on January 15, 2029, with payout tied to MannKind’s total shareholder return versus the Russell 3000 Pharmaceutical & Biotechnology Index from April 1, 2026 to December 31, 2028. Payout ranges from 0% to 300% of the 221,000-target based on percentile rankings.
Thomson was also granted stock options for 217,000 shares at an exercise price of $2.44 per share, vesting 25% on March 23, 2027 and then 1/16 quarterly through March 23, 2031.
MannKind Corp CEO Michael Castagna purchased 100,000 shares of common stock in an open-market transaction at a weighted average price of $2.59 per share on March 10, 2026. Following this purchase, he directly owns 2,575,911 shares. An additional 1,500 shares are held indirectly through his spouse.
MannKind Corp director Shannon James Samuel acquired 12,000 shares of common stock at a price of $3.27 per share. The acquisition was made through the company’s Market Price Stock Purchase Plan, which was approved by the Board of Directors on March 1, 2026.
Following this grant or award acquisition, Samuel’s direct holdings increased to 64,635 shares of MannKind common stock. This transaction reflects participation in a board-approved stock purchase plan rather than an open-market trading decision.
MannKind Corp director Anthony C. Hooper acquired 35,000 shares of common stock on March 1, 2026 at a price of $3.27 per share. The shares were purchased through the company’s Market Price Stock Purchase Plan, which was approved by the board on that date. Following this transaction, Hooper directly owns 236,153 MannKind shares.
MannKind Corp's Chief Financial Officer Christopher B. Prentiss acquired additional company stock through a board-approved purchase plan. On March 1, 2026, he obtained 5,000 shares of common stock at $3.27 per share under the Market Price Stock Purchase Plan. Following this transaction, he directly owned 348,854 shares of MannKind common stock.